The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why the issue is hotly debated.
Subscribe to our e-newsletterVIEW OUR CURRENT ISSUE >
TagsBIOTECH global food crisis Benefits of biotech crops climate change Animal biotechnology BIO EVENT Health Care biofuels FDA Food health GMOs Plant biotechnology healthcare biotech industry public policy Sustainability biotechnology agriculture BIO Investor Forum
- Most Popular
Latest VideoWhat's Hot & What's Not in Oncology Licensing (a web panel co-sponsored by BIO and ShareVault) View All >